
Sign up to save your podcasts
Or


All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.
By Lemonada Media4.6
34723,472 ratings
All eyes are on the Supreme Court this week, as the temporary stay in the Texas mifepristone case expires. Andy speaks with Fatima Goss Graves from the National Women’s Law Center about the confusing rulings and what she expects the justices to do. Former FDA Commissioner Josh Sharfstein also joins to explain the dangerous precedent this case could set for FDA-approved drugs and drug development.
Keep up with Andy on Post and Twitter @ASlavitt.
Follow Fatima Goss Graves and Joshua Sharfstein on Twitter @FGossGraves and @drJoshS.
Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.
Support the show by checking out our sponsors!
Check out these resources from today’s episode:
Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.
For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.
See omnystudio.com/listener for privacy information.

37,218 Listeners

3,554 Listeners

87,912 Listeners

32,411 Listeners

9,384 Listeners

2,859 Listeners

12,748 Listeners

8,597 Listeners

319 Listeners

5,115 Listeners

762 Listeners

598 Listeners

16,446 Listeners

10,529 Listeners

861 Listeners

3,481 Listeners

387 Listeners

243 Listeners

10,897 Listeners

88 Listeners

119 Listeners

1,886 Listeners

449 Listeners

7,058 Listeners

1,185 Listeners

6,287 Listeners

618 Listeners

87 Listeners

464 Listeners

46 Listeners

151 Listeners

76 Listeners

23 Listeners

4,261 Listeners